Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
NCT ID: NCT03144037
Last Updated: 2021-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
152 participants
OBSERVATIONAL
2017-04-26
2021-03-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
NCT01081509
A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer
NCT04086875
Interactive Care Plan for the Monitoring of Symptoms and Recovery in Patients With Stage 0-III Breast Cancer
NCT04693338
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
NCT04379570
An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment
NCT00737009
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0).
* Patients must be on one of AI (steroidal or non-steroidal).
* Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery.
* Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery.
* Patient must be on one of AI (steroidal or non-steroidal).
* Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Texas Tech University Health Sciences Center, El Paso
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Philipovskiy
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexander Philipovskiy, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Texas Tech University Health Sciences Center, El Paso
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Texas Tech University HSC El Paso
El Paso, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E17086
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.